Skip to main content

Advertisement

SpringerLink
Log in

Pharmacological Treatment of Voiding Dysfunction in Older Men

  • Geriatric Urology (TJ Guzzo and DJ Canter, Section Editors)
  • Published:
Current Geriatrics Reports Aims and scope Submit manuscript

Abstract

Lower urinary tract symptoms are common in the male population, and prevalence increases in association with increasing age. Voiding, rather than storage symptoms, are more common in men although this disparity levels out in very late life. Pharmacological treatment of voiding dysfunction in men has concentrated on reducing the effects of the progressive bladder outflow tract obstruction created by the age-associated enlargement of the prostate. There is a wealth of evidence supporting the use of pharmacological therapy from clinical trials which have mostly included men in mid-life but up until relatively recently there has been little research in this area which has specifically addressed the needs of older men. Data on men with comorbidities come from observational studies, and there has been no routine reporting of disease or drug burden in the treated samples. This article reviews the evidence for pharmacological therapy for voiding dysfunction in older men and highlights the limitations in that evidence.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Chapple CR, Roehrborn CG. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol. 2006;49(4):651–8.

    Article  PubMed  Google Scholar 

  2. Emberton M, Cornel EB, Bassi PF, Fourcade RO, Gomez JM, Castro R. Benign prostatic hyperplasia as a progressive disease: a guide to the risk factors and options for medical management. Int J Clin Pract. 2008;62(7):1076–86.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  3. Robertson C, Link CL, Onel E, et al. The impact of lower urinary tract symptoms and comorbidities on quality of life: the BACH and UREPIK studies. BJU Int. 2007;99(2):347–54.

    Article  PubMed  Google Scholar 

  4. Chute CG, Panser LA, Girman CJ, et al. The prevalence of prostatism: a population-based survey of urinary symptoms. J Urol. 1993;150(1):85–9.

    CAS  PubMed  Google Scholar 

  5. Penson DF, Munro HM, Signorello LB, Blot WJ, Fowke JH. Obesity, physical activity and lower urinary tract symptoms: results from the southern community cohort study. J Urol. 2011;186(6):2316–22.

    Article  PubMed Central  PubMed  Google Scholar 

  6. Irwin DE, Milsom I, Hunskaar S, et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol. 2006;50(6):1306–14. discussion 1314–1305.

    Article  PubMed  Google Scholar 

  7. Poyhonen A, Hakkinen JT, Koskimaki J, Hakama M, Tammela TL, Auvinen A. Prevalence of hesitancy in 30-80-year-old Finnish men: Tampere ageing Male Urological Study (TAMUS). BJU Int. 2012;109(9):1360–4.

    Article  PubMed  Google Scholar 

  8. Wagg A, Gibson W, Ostaszkiewicz J, et al. Urinary incontinence in frail elderly persons: Report from the 5th International Consultation on Incontinence. Neurourology and Urodynamics. Apr 2 2014. Essentially the only guideline which considers frail older persons in the context of multimorbidity.

  9. Bylund DB, Eikenberg DC, Hieble JP, et al. International Union of Pharmacology nomenclature of adrenoceptors. Pharmacol Rev. 1994;46(2):121–36.

    CAS  PubMed  Google Scholar 

  10. Moriyama N, Kurimoto S, Horie S, et al. Detection of alpha 1-adrenoceptor subtypes in human hypertrophied prostate by in situ hybridization. Histochem J. 1996;28(4):283–8.

    Article  CAS  PubMed  Google Scholar 

  11. Chen Q, Takahashi S, Zhong S, et al. Function of the lower urinary tract in mice lacking alpha1d-adrenoceptor. J Urol. 2005;174(1):370–4.

    Article  CAS  PubMed  Google Scholar 

  12. Nomiya M, Yamaguchi O. A quantitative analysis of mRNA expression of alpha 1 and beta-adrenoceptor subtypes and their functional roles in human normal and obstructed bladders. J Urol. 2003;170(2 Pt 1):649–53.

    Article  CAS  PubMed  Google Scholar 

  13. Bouchelouche K, Andersen L, Alvarez S, Nordling J, Bouchelouche P. Increased contractile response to phenylephrine in detrusor of patients with bladder outlet obstruction: effect of the alpha1A and alpha1D-adrenergic receptor antagonist tamsulosin. J Urol. 2005;173(2):657–61.

    Article  CAS  PubMed  Google Scholar 

  14. Kojima Y, Sasaki S, Imura M, Kubota Y, Hayashi Y, Kohri K. Correlation between expression of alpha(1)-adrenoceptor subtype mRNA and severity of lower urinary tract symptoms or bladder outlet obstruction in benign prostatic hyperplasia patients. BJU Int. 2011;107(3):438–42.

    Article  PubMed  Google Scholar 

  15. Barendrecht MM, Abrams P, Schumacher H, de la Rosette JJ, Michel MC. Do alpha1-adrenoceptor antagonists improve lower urinary tract symptoms by reducing bladder outlet resistance? Neurourol Urodyn. 2008;27(3):226–30.

    Article  CAS  PubMed  Google Scholar 

  16. Kortmann BB, Floratos DL, Kiemeney LA, Wijkstra H, de la Rosette JJ. Urodynamic effects of alpha-adrenoceptor blockers: a review of clinical trials. Urology. 2003;62(1):1–9.

    Article  PubMed  Google Scholar 

  17. Schwinn DA, Roehrborn CG. Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008;15(3):193–9.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  18. Michel MC, Bressel HU, Mehlburger L, Goepel M. Tamsulosin: real life clinical experience in 19,365 patients. Eur Urol. 1998;34 Suppl 2:37–45. Although old, this is one of the few studies which addresses comorbidity in a systematic manner.

    Article  CAS  PubMed  Google Scholar 

  19. Djavan B, Chapple C, Milani S, Marberger M. State of the art on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Urology. 2004;64(6):1081–8.

    Article  PubMed  Google Scholar 

  20. Nickel JC, Sander S, Moon TD. A meta-analysis of the vascular-related safety profile and efficacy of alpha-adrenergic blockers for symptoms related to benign prostatic hyperplasia. Int J Clin Pract. 2008;62(10):1547–59.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  21. Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernandez FE. Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol. 2011;59(3):342–52.

    Article  CAS  PubMed  Google Scholar 

  22. MacDonald R, Wilt TJ. Alfuzosin for treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia: a systematic review of efficacy and adverse effects. Urology. 2005;66(4):780–8.

    Article  PubMed  Google Scholar 

  23. Shirakawa T, Haraguchi T, Shigemura K, et al. Silodosin versus naftopidil in Japanese patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized multicenter study. Int J Urol Off J Japan Urol Assoc. 2013;20(9):903–10.

    CAS  Google Scholar 

  24. Watanabe T, Ozono S, Kageyama S. A randomized crossover study comparing patient preference for tamsulosin and silodosin in patients with lower urinary tract symptoms associated with benign prostatic hyperplasia. J Int Med Res. 2011;39(1):129–42.

    Article  CAS  PubMed  Google Scholar 

  25. Yokoyama T, Hara R, Fukumoto K, et al. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia. Int J Urol Off J Japan Urol Assoc. 2011;18(3):225–30.

    CAS  Google Scholar 

  26. Bird ST, Delaney JA, Brophy JM, Etminan M, Skeldon SC, Hartzema AG. Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40–85 years in the United States: risk window analyses using between and within patient methodology. BMJ. 2013;347:f6320.

    Article  PubMed Central  PubMed  Google Scholar 

  27. Oelke M, Gericke A, Michel MC, Oelke M, Gericke A, Michel MC. Cardiovascular and ocular safety of alpha1-adrenoceptor antagonists in the treatment of male lower urinary tract symptoms. Expert Opin Drug Saf. 2014;13(9):1187–97. Excellent review of overall safety.

    Article  CAS  PubMed  Google Scholar 

  28. Kupelian V, McVary KT, Kaplan SA, et al. Association of lower urinary tract symptoms and the metabolic syndrome: results from the Boston area community health survey. J Urol. 2013;189(1 Suppl):S107–114. discussion S115-106.

    Article  PubMed  Google Scholar 

  29. Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L. Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia and on erectile dysfunction in sexually active men with both conditions: analyses of pooled data from four randomized, placebo-controlled tadalafil clinical studies. J Sex Med. 2013;10(8):2044–52.

    Article  PubMed  Google Scholar 

  30. McVary KT, Roehrborn CG, Kaminetsky JC, et al. Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol. 2007;177(4):1401–7.

    Article  CAS  PubMed  Google Scholar 

  31. Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L. Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol. 2012;61(5):917–25. Establishes the utility of this group of drugs for LUTS.

    Article  CAS  PubMed  Google Scholar 

  32. Oelke M, Giuliano F, Baygani SK, Melby T, Sontag A. Treatment satisfaction with tadalafil or tamsulosin vs placebo in men with lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH): results from a randomised, placebo-controlled study. BJU Int. 2014;114(4):568–75.

    Article  CAS  PubMed  Google Scholar 

  33. Casabe A, Roehrborn CG, Da Pozzo LF, et al. Efficacy and safety of the coadministration of tadalafil once daily with finasteride for 6 months in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia. J Urol. 2014;191(3):727–33.

    Article  CAS  PubMed  Google Scholar 

  34. Naslund MJ, Miner M. A review of the clinical efficacy and safety of 5alpha-reductase inhibitors for the enlarged prostate. Clin Ther. 2007;29(1):17–25.

    Article  CAS  PubMed  Google Scholar 

  35. Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS. Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int. 2011;108(3):388–94.

    Article  CAS  PubMed  Google Scholar 

  36. Roehrborn CG, Siami P, Barkin J, et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol. 2010;57(1):123–31.

    Article  PubMed  Google Scholar 

  37. Roehrborn CG, Barkin J, Tubaro A, et al. Influence of baseline variables on changes in international prostate symptom score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study. BJU Int. 2014;113(4):623–35.

    Article  CAS  PubMed  Google Scholar 

  38. McConnell JD, Roehrborn CG, Bautista OM, et al. The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med. 2003;349(25):2387–98.

    Article  CAS  PubMed  Google Scholar 

  39. Fwu CW, Eggers PW, Kaplan SA, Kirkali Z, Lee JY, Kusek JW. Long-term effects of doxazosin, finasteride and combination therapy on quality of life in men with benign prostatic hyperplasia. J Urol. 2013;190(1):187–93.

    Article  CAS  PubMed  Google Scholar 

  40. Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int. 2013;111(2):304–11.

    Article  CAS  PubMed  Google Scholar 

  41. Griffin MR. Epidemiology of nonsteroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med. 1998;104(3A):23S–29

  42. Yassin AA, El-Sakka AI, Saad F, Gooren LJ. Lower urinary-tract symptoms and testosterone in elderly men. World J Urol. 2008;26(4):359–64.

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  43. Kuo HC. Botulinum A, toxin urethral injection for the treatment of lower urinary tract dysfunction. J Urol. 2003;170(5):1908–12.

    Article  CAS  PubMed  Google Scholar 

  44. Abrams PH, Fall M, Cardozo L, et al. The standardization of terminology of lower urinary tract function: report from the standardization sub-committee of the international continence society. Neurourol Urodyn. 2002;21:167–78.

    Article  PubMed  Google Scholar 

  45. Cucchi A, Quaglini S, Rovereto B. Proposal for a urodynamic redefinition of detrusor underactivity. J Urol. 2009;181(1):225–9.

    Article  PubMed  Google Scholar 

  46. Madersbacher S, Pycha A, Schatzl G, Mian C, Klingler CH, Marberger M. The aging lower urinary tract: a comparative urodynamic study of men and women. Urology. 1998;51(2):206–12.

    Article  CAS  PubMed  Google Scholar 

  47. Malone-Lee J, Wahedna I. Characterisation of detrusor contractile function in relation to old-age. Br J Urol. 1993;72:873–80.

    Article  CAS  PubMed  Google Scholar 

  48. Bonde HV, Sejr T, Erdmann L, et al. Residual urine in 75-year-old men and women. A normative population study. Scand J Urol Nephrol. 1996;30(2):89–91.

    Article  CAS  PubMed  Google Scholar 

  49. Jeong SJ, Kim HJ, Lee YJ, et al. Prevalence and clinical features of detrusor underactivity among elderly with lower urinary tract symptoms: a comparison between men and women. Korean J Urol. 2012;53(5):342–8.

    Article  PubMed Central  PubMed  Google Scholar 

  50. Resnick NM, Elbadawi AE, Yalla SV. Age and the lower urinary tract: what is normal? NeurourolUrodyn. 1995;14:1647.

    Google Scholar 

  51. Ameda K, Sullivan MP, Bae RJ, Yalla SV. Urodynamic characterization of nonobstructive voiding dysfunction in symptomatic elderly men. J Urol. 1999;162(1):142–6.

    Article  CAS  PubMed  Google Scholar 

  52. Susset JG, Servot-Viguier D, Lamy F, Madernas P, Black R. Collagen in 155 human bladders. Invest Urol. 1978;16(3):204–6.

    CAS  PubMed  Google Scholar 

  53. Fry CH, Bayliss M, Young JS, Hussain M. Influence of age and bladder dysfunction on the contractile properties of isolated human detrusor smooth muscle. BJU Int. 2011;108(2 Pt 2):E91–96.

    Article  PubMed  Google Scholar 

  54. Collas D, Malone-Lee JG. Age associated changes in detrusor sensory function in patients with lower urinary tract symptoms. Int Urogynecol J Pelvic Floor Dysfunct. 1996;7:24–9.

    Article  CAS  PubMed  Google Scholar 

  55. Griffiths D, Tadic SD. Bladder control, urgency, and urge incontinence: evidence from functional brain imaging. NeurourolUrodyn. 2008;27(6):466–74.

    Google Scholar 

  56. Izumi K, Maolake A, Maeda Y, Shigehara K, Namiki M. Effects of bethanechol chloride and distigmine bromide on postvoiding residual volume in patients with underactive bladder. Minerva Urol Nefrol Ital J Urol Nephrol. 2014;66(4):241–7.

    CAS  Google Scholar 

  57. Hindley RG, Brierly RD, Thomas PJ. Prostaglandin E2 and bethanechol in combination for treating detrusor underactivity. BJU Int. 2004;93(1):89–92.

    Article  CAS  PubMed  Google Scholar 

  58. Sugaya K, Kadekawa K, Onaga T, et al. Effect of distigmine at 5 mg daily in patients with detrusor underactivity. Nihon Hinyokika Gakkai Zasshi. 2014;105(1):10–6.

    PubMed  Google Scholar 

Download references

Compliance with Ethics Guidelines

Conflict of Interest

Adrian Wagg has received compensation from Astellas Pharma, Pfizer, and SCA for service as a consultant; has received honoraria from Astellas Pharma, Pfizer, and SCA; has received speaker’s honoraria from Merus Labs and has received financial support through research grants from Astellas Pharma.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Author information

Authors and Affiliations

  1. Department of Medicine, Division of Geriatric Medicine, University of Alberta, 1-108, Clinical Sciences Building, 11350 – 83 Avenue, Edmonton, AB, T6G 2P4, Canada

    Adrian Wagg

Authors
  1. Adrian Wagg
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Adrian Wagg.

Additional information

This article is part of the Topical Collection on Geriatric Urology

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Wagg, A. Pharmacological Treatment of Voiding Dysfunction in Older Men. Curr Geri Rep 4, 44–50 (2015). https://doi.org/10.1007/s13670-015-0119-8

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13670-015-0119-8

Keywords

Search

Navigation